Erratum: Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial (American Journal of Respiratory and Critical Care Medicine (2019) 199 (980–986) DOI: 10.1164/rccm.201807-1419OC);Transcriptomic signatures in sepsis and a differential response to steroids from the VaNISH randomized trial

American Journal of Respiratory and Critical Care Medicine

Volumn 199, Issue 8, 2019, Pages 980-986

  Antcliffe, David B ^a,b   Burnham, Katie L ^c   Al Beidh, Farah ^a   Santhakumaran, Shalini ^a   Brett, Stephen J ^b   Hinds, Charles J ^d   Ashby, Deborah ^a   Knight, Julian C ^c   Gordon, Anthony C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Corticosteroids; Norepinephrine; Sepsis; Transcriptomics; Vasopressin

Indexed keywords

HYDROCORTISONE; NORADRENALIN; TRANSCRIPTOME; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; TRANSCRIPTOMICS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; IMMUNOCOMPETENCE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SURVIVAL ANALYSIS;

AGED; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION PROFILING; HUMANS; HYDROCORTISONE; IMMUNOCOMPETENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NOREPINEPHRINE; PHENOTYPE; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TRANSCRIPTOME; VASOPRESSINS;

EID: 85056395172     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.v206erratum10     Document Type: Erratum

References (19)

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–810.
2. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al.; ADRENAL Trial Investigators and the Australian–New Zealand Intensive Care Society Clinical Trials Group. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018;378:797–808.
3. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot J-P, Siami S, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018;378:809–818.
4. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016;4:259–271.
5. Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC, Hutton P, et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med 2017;196:328–339.
6. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al.; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016;316:509–518.
7. Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ. Protocol for a randomised controlled trial of vasopressin versus noradrenaline as initial therapy in septic shock (VANISH). BMJ Open 2014;4:e005866.
8. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al.; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111–124.
9. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
10. Cox DR, Snell EJ. Analysis of binary data, 2nd ed. London: Chapman & Hall; 1989.
11. Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 2014;42:1325–1333.
12. Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 2004;169:1144–1151.
13. Lim TK, Chen GH, McDonald RA, Toews GB. Granulocyte-macrophage colony–stimulating factor overrides the immunosuppressive function of corticosteroids on rat pulmonary dendritic cells. Stem Cells 1996; 14:292–299.
14. van de Garde MDB, Martinez FO, Melgert BN, Hylkema MN, Jonkers RE, Hamann J. Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction. J Immunol 2014;192:1196–1208.
15. Leung DYM, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003;111:3–22, quiz 23.
16. Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, et al.; CHI Consortium. Corrigendum: effects of systemically administered hydrocortisone on the human immunome. Sci Rep 2016;6:25215.
17. Conway Morris A, Datta D, Shankar-Hari M, Stephen J, Weir CJ, Rennie J, et al. Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med 2018;44:627–635.
18. Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med 2015;191:309–315.
19. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med 2018;46:915–925.